Medpace (NASDAQ: MEDP) and Blueprint Medicines (NASDAQ:BPMC) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for Medpace and Blueprint Medicines, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medpace 0 6 1 0 2.14
Blueprint Medicines 0 0 10 0 3.00

Medpace presently has a consensus target price of $35.75, indicating a potential downside of 4.87%. Blueprint Medicines has a consensus target price of $83.78, indicating a potential upside of 14.33%. Given Blueprint Medicines’ stronger consensus rating and higher possible upside, analysts clearly believe Blueprint Medicines is more favorable than Medpace.

Valuation & Earnings

This table compares Medpace and Blueprint Medicines’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medpace $421.58 million 3.35 $13.42 million $0.69 54.46
Blueprint Medicines $27.77 million 113.15 -$72.49 million ($3.42) -21.43

Medpace has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medpace and Blueprint Medicines’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Medpace 6.44% 10.00% 6.19%
Blueprint Medicines -437.83% -43.11% -34.38%

Insider & Institutional Ownership

16.8% of Medpace shares are owned by institutional investors. Comparatively, 83.5% of Blueprint Medicines shares are owned by institutional investors. 25.8% of Medpace shares are owned by insiders. Comparatively, 3.4% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Medpace beats Blueprint Medicines on 8 of the 13 factors compared between the two stocks.

Medpace Company Profile

Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.